written by reader $16. stock you should buy now, from Tilson

By orvillew, July 10, 2020

Anyone know the $16 stock that will revolutionize organ transplants as teased to see some newsletter, Prof Litman, Altimetry, I am being pitched by Tilson and Standsberry

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

8
Share your thoughts...

avatar
5 Comment threads
3 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
6 Comment authors
timothylarsenKenneth Murraybunion132orvillewjoeycoco Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

lael
Member
๐Ÿ‘32
lael

Just did a quick google search, no actual analysis. But my guess would be TMDX? Anybody care to verify?

lael
Member
๐Ÿ‘32
lael

There even was some increased trading volume this morning with the newsletter release.

bunion132
Irregular
๐Ÿ‘260

I, too, watched Prof. Joel Litman’s (Microcap Confidential)video in collaboration with Stansberry a couple of nights ago. The only clues Litman gave were that the stock is in the healthcare sector and in the $16 range. If Whitney Tilson is pitching the same stock, it helps that he narrowed it down to organ transplants and TMDX fits in well with these limited clues. Litman showed a simple graph comparing the stock’s REPORTED Return on Assets (ROA) vs the “TRUE” ROA of the stock had the company not used the unreliable GAAP accounting method. However, the bar graph showed a Reported… Read More ยป

joeycoco
Irregular
๐Ÿ‘0
joeycoco

Would love to know this as well, I tried the usual search methods but came up empty.

Kenneth Murray
Guest
Kenneth Murray

Still no clarity on this? Can anyone pin it down?

timothylarsen
Irregular
๐Ÿ‘0
timothylarsen

I actually think it might be Mylan (MYL). Mylan has a generic organ transplant drug. If you search “Joel Litman’s Long Convictions List” it will pull up a document from 2017 in which he outlines his most bullish bets, and one of them is Mylan.